PRIMARY STUDY
The Use of Cannabinoids in Colitis: A Systematic Review and Meta-Analysis.
Key Findings: The review suggests there is abundant preclinical literature demonstrating the anti-inflammatory effects of cannabinoid drugs in inflammation of the gut. Larger randomised controlled-trials are warranted. Cannabidiol, a phytocannabinoid, was the most investigated drug.
Type of Study: Meta-analysis
Study Result: Positive
Research Location(s): United Kingdom
Year of Pub: 2018
Cannabinoids Studied: Cannabidiol (CBD), Cannabigerol (CBG), AM-x Synthetic Cannabinoids, WIN-x Synthetic Cannabinoids, Anandamide (AEA), Cannabinoid (unspecified), Synthetic Cannabinoid (unspecified)
Phytocannabinoid Source: Not Applicable
Citation: Couch DG, et al. The Use of Cannabinoids in Colitis: A Systematic Review and Meta-Analysis. Inflamm Bowel Dis. 2018; 24:680-697. doi: 10.1093/ibd/izy014
Authors: Couch DG, Maudslay H, Doleman B, Lund JN, O'Sullivan SE
